Shalby Limited (NSE:SHALBY)
India
· Delayed Price · Currency is INR 186.29
-0.02 (-0.01%)
Jul 4, 2025, 3:29 PM IST
Shalby Revenue
In the fiscal year ending March 31, 2025, Shalby had annual revenue of 10.87B INR with 16.41% growth. Shalby had revenue of 2.65B in the quarter ending March 31, 2025, with 8.46% growth.
Revenue
10.87B
Revenue Growth
+16.41%
P/S Ratio
1.84
Revenue / Employee
3.81M
Employees
2,853
Market Cap
20.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 10.87B | 1.53B | 16.41% |
| Mar 31, 2024 | 9.34B | 1.29B | 16.00% |
| Mar 31, 2023 | 8.05B | 1.06B | 15.16% |
| Mar 31, 2022 | 6.99B | 2.68B | 62.21% |
| Mar 31, 2021 | 4.31B | -559.57M | -11.49% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 272.67B |
| Apollo Hospitals Enterprise | 217.94B |
| Zydus Lifesciences | 232.42B |
| Mankind Pharma | 122.07B |
| Aurobindo Pharma | 317.24B |
| Fortis Healthcare | 77.83B |
Shalby News
- 5 months ago - Q3 2025 Shalby Ltd Earnings Call Transcript - GuruFocus
- 5 months ago - Shalby shares drop 4% as EBITDA falls 20.1% YoY in Q3 - Business Upturn
- 6 months ago - Shalby shares jump 3% after FDA approval for Duraniom knee replacement device - Business Upturn
- 11 months ago - Monogram Technologies announces strategic collaboration with Shalby Limited - Seeking Alpha